Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

類似資料

• Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia
  著者:: Bhavnani, Sujata M., 等
  出版事項: (2006)
• Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections
  著者:: Bhavnani, Sujata M., 等
  出版事項: (2014)
• Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia
  著者:: Rubino, Christopher M., 等
  出版事項: (2010)
• Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose
  著者:: Fetterly, Gerald J., 等
  出版事項: (2005)
• Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials
  著者:: Rubino, C. M., 等
  出版事項: (2015)